A ortic valve stenosis (AS) is the primary valve disease with the highest prevalence in industrialized countries. 1 A European survey on patients with valvular disease revealed that up to 30% of patients with severe symptomatic AS and a class I indication for aortic valve replacement (AVR) did not receive such treatment owing to factors like age, comorbidities, and estimated dismal prognosis. 2 With the advent of transcatheter AVR, alternative treatment options are now available, especially for old, frail, and high-risk patients. Prognosis of severe AS has brightened in the past decade owing to improved risk factor control and cardiovascular therapies combined with lower perioperative mortality. 3 Main criteria in the European and American guidelines for the management of patients with valvular heart disease evaluate severity and prognosis of AS by aortic valve area, pressure gradient, and parameters of global LV systolic function (eg, ejection fraction [EF] ) and rely less on irreversible structural myocardial damage or detailed left ventricular (LV) functional assessment. 4, 5 In the course of disease progression, pressure overload and high ventricular wall stress eventually exceeds compensatory LV hypertrophy. [6] [7] [8] [9] LV hypertrophy will become maladaptive, leading to reduced myocardial perfusion and myocyte destruction with subsequent development of myocardial replacement fibrosis (MRF), which indicates with a certain amount and degree of fibrosis a decompensated stage of the disease. 10 Replacement fibrosis is a result of a multitude of stressors to the heart, such as ischemia, pressure, and volume overload. It promotes a deterioration of cardiac chamber geometry, myocyte hypertrophy, and cardiac compliance. 11 Replacement fibrosis promotes heart failure, arrhythmia, sudden cardiac death, and high perioperative mortality. [11] [12] [13] [14] Several studies have shown that myocardial structural and functional correlates of fibrosis, detected by echocardiography or cardiovascular magnetic resonance (CMR), are independent predictors of mortality risk in patients with AS. [14] [15] [16] Further, replacement fibrosis in AS seems irreversible and is thought to develop way before EF starts to decrease and symptoms emerge. Recent guidelines on AS treatment still lack recommendations about the inclusion of replacement fibrosis in the clinical workup. Previously, we reported on the role of replacement fibrosis in severe symptomatic AS and the role of replacement fibrosis in low-gradient AS about short-term outcome. 7, 14 However, prospective data on long-term prognosis after AVR is still scarce. Therefore, we performed in extension to our earlier data published in 2009, a 10-year follow-up on patients who underwent AVR because of symptomatic AS. We aimed to delineate the impact of replacement fibrosis and further risk factors on long-term prognosis.
METHODS
The data, analytic methods, and study materials will not be made available in public to other researchers only in case of a specific request from a reader or reviewer. The following sections are a summary of the study methodology, as well as the baseline and 9 months' data published by our group in 2009, which are now enhanced by 10-year follow-up. 14 
Study Population
This clinical prospective study included consecutive patients with symptomatic severe AS referred to the Würzburg University Hospital between March 2006 and February 2007 for left-sided heart catheterization and evaluation before AVR. Patients were eligible if they exhibited isolated severe AS defined as symptoms on exertion and an aortic valve area below 1.0 cm 2 . Patients with previous myocardial infarction, significant coronary artery disease (degree of stenosis >50%), prior heart surgery, malignant cancer, or other valvulopathies greater than stage I were excluded. One hundred patients were screened, and 58 patients were included in the study. Survival status was assessed either during routine follow-up visits (n=34) or via telephone interviews with the patient or a family member, conducted from February 2017 to April 2017, or by inspection of death certificates (n=23).
Study Protocol
Within 3 days after heart catheterization, all subjects were examined by echocardiography, including measurement of mitral ring displacement (assessment of longitudinal wall function), EF (assessment of global LV function), strain rate imaging (assessment of regional LV function), and CMR (assessment of replacement fibrosis).Within the next 3 weeks,
CLINICAL PERSPECTIVE
In patients with severe aortic valve stenosis replacement fibrosis indicating myocardial injury seems to be irreversible and frequently progressive. The exact quantification of the total amount of myocardial fibrosis is methodically challenging and seems of secondary importance for prognostic profiling. Rather, a detailed noninvasive assessment should be used to quantify the underlying functional consequences, which are best reflected by longitudinal strain rate and mitral annulus displacement. This is likely of particular importance for a comprehensive preoperative risk assessment to avoid delay in aortic valve replacement. It remains to be shown in future studies if this workup helps to select patients that would benefit from an early valve replacement before left ventricular function deteriorates and symptoms develop.
AVR was performed on all patients, and 2 endomyocardial biopsies were taken intraoperatively from the endocardium of the basal LV septum (assessment of replacement fibrosis). Nine months and 10 years after AVR, patients were invited to attend follow-up studies, including clinical examination, venous blood samples, echocardiography, and CMR. Baseline data and 9-month follow-up data were already published earlier in 2009. 7 The study was approved by an international review board/international ethics committee and conformed to the principles outlined in the Declaration of Helsinki. An informed consent was obtained from all patients before any investigation and before the 10-year follow-up again.
Heart Catheterization
Selective coronary angiography was performed with 5F catheters via a right femoral artery approach (Cordis, Miami, FL). Systolic and end-diastolic LV pressure recordings were made with fluid-filled pigtail catheters after retrograde passage of the aortic valve. After the pigtail catheter in the ascending aorta was pulled back, the peak systolic pressure gradient was calculated. Through the use of a venous approach, right heart catheterization was performed using a Swan-Ganz catheter measuring wedge pressure in wedge position. Stroke volume was calculated using thermodilution method.
Standard Echocardiography
Transthoracic echocardiography was performed with a VIVID 7 and E9 3.5-MHz ultrasound scanner (GE Ultrasound, Horten, Norway). A standard echocardiographic study for the evaluation of left and right heart dimensions and valvular heart disease was done. Left atrial, LV end-diastolic, and end-systolic dimensions, as well as end-diastolic thickness of the posterior wall and septum, were measured from parasternal LV long-axis images. EF was calculated using Simpson's modified biplane method. Aortic valve area was calculated using the continuity equation according to American Heart Association guidelines. 5 Blood-pool pulsed Doppler of the mitral valve inflow was used to extract the ratio of early to late diastolic flow velocity (E/A) and the deceleration time. Early diastolic septal and lateral mitral ring motion (E´) were extracted by pulsed-wave tissue Doppler imaging, and the E/E´ ratio was calculated. Systolic mitral ring displacement was measured at the septal and lateral side with M-mode echocardiography in apical 4-chamber view and served as a surrogate of the overall systolic longitudinal function of the septum. The reproducibility of this parameter was examined by triple (intraobserver) and double (interobserver) measurements of 10 different patients, yielding coefficients of variation of 5.5% and 6.3% for intraobserver and interobserver reproducibility, respectively.
Strain Rate Imaging
Real-time 2-dimensional color Doppler myocardial imaging data were recorded from the interventricular septum using a standard apical 4-chamber view to evaluate longitudinal function. To assess radial function of the posterior wall, parasternal long-axis views were used. Because this method is angle dependent, care was taken that the investigated myocardium and the ultrasound beam were aligned to nearly 0°. Data were analyzed with dedicated software (Echopac, GE Ultrasound). Strain rate curves were extracted for the basal septum (longitudinal function) and the basal posterior wall (radial function). Strain rate profiles were averaged over 3 consecutive cardiac cycles and integrated over time to derive natural strain profiles with end diastole as the reference point. From the averaged strain rate and strain data, systolic strain (related to regional stroke volume) and peak systolic strain rate (related to regional contractility) was calculated.
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CMR Studies
CMR was performed in all patients without contraindications (baseline, n=46; 9 months, n=42; and 10 years, n=16). For detection of fibrosis, phase-sensitive inversion recovery images (field of view, 240×320 mm 2 ; matrix size, 165×256) were acquired 12 to 15 minutes after the injection of gadopentetate dimeglumine (Magnevist, Schering, Berlin, Germany; 0.2 mmol/kg body weight). A stack of multiple short-axis views covering the entire LV was applied to detect changes in tissue integrity of LV myocardium. 17 Quantitative determination of MRF was performed for all LV segments using a workstation with commercial available postprocessing software for magnetic resonance imaging (CVI 42, Circle Cardiovascular Imaging Inc, Calgary, Canada). A semiautomatic estimation of enhanced fibrotic areas was identified as 3 SDs above the mean value of viable myocardium. The percentage of fibrotic to viable myocardial tissue was determined quantitatively for each segment. In an initial clinical study, focal late enhancement could be observed in the hypertrophic myocardium of patients with aortic stenosis.
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Grading of Endomyocardial Biopsies and Grouping Procedure
Patients were divided into 3 groups based on the histological result of the biopsies taken during AVR. After formalin fixation and paraffin embedding, 5 µm sections were performed and stained by Ladewig's trichrome staining. Fifty high-power fields were analyzed for the density of collagen fibers using the equipment, software, and digitalization settings as mentioned in the reference below. 19 The diameters of the cardiomyocytes were analyzed as previously described, averaging the orthogonal diameters of 50 cardiomyocytes detected in cross sections. 20 For the histological analysis, both endomyocardial biopsies were used. Percentage area of fibrosis was calculated and used as the index of the degree of fibrosis. The percentage area of fibrosis in the section was obtained by dividing the sum of the fibrotic areas of the section by that of the total tissue area as described by Tanaka et al. 21 According to this fibrosis index, 22 patients were classified as having no fibrosis, 15 as having mild fibrosis, and 21 as having severe fibrosis.
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Data Analysis
Data are presented as mean (SD), median (25th to 75th percentile), or frequency (percent) as appropriate. Echocardiography and CMR analysis were performed blinded with respect to the evaluation of New York Heart Association (NYHA) functional class and to the amount of fibrosis assessed by myocardial Left heart catheterization:
Pulmocapillary wedge pressure, mm Hg 13 (9) 13 (7) 16 (6) 0.170
Left ventricular systolic pressure, mm Hg 204 (16) 198 (14) 175 (20) <0.001
Stroke volume, mL 82 (16) 67 (22) 61 (19) 0.002
Peak to peak gradient, mm Hg 56 (14) 57 (13) 51 (20) 0.449
Mean gradient, mm Hg 53 (9) 48 (9) 36 (8) 0.090
Ejection fraction, % 55 (10) 57 (5) 52 (14) Values are mean (SD), unless indicated otherwise. E/A indicates ratio of early to late flow via the mitral valve; E/E´, ratio of early diastolic mitral flow to early; MRI, magnetic resonance imaging; and NYHA, New York Heart Association.
*Total cholesterol >200 mg/dL or on lipid-lowering drug. †Continuity equation.
biopsies. Variables with non-normal distribution were log normalized before linear regression was performed. We used χ 2 tests for linear trend or linear regression analyses to compute probability values for trend across the categories of fibrosis in Table 1 . Because 25 variables were assessed, the level of statistical significance was set to 0.002 (Table 1) . Correlations were computed using Spearman's correlation coefficient. Changes in hemodynamic variables from baseline to follow-up were tested by ANCOVA, with the difference as the dependent variable, group as the factor, and baseline variable as the covariate. Post hoc significance was tested with the Waller-Duncan t test, which uses the Bayesian method to take into account unequal group sizes. ANOVA for repeated measurements was used to compute the probability values presented in Table 2 . Because of the small size, no statistics were computed for the 10-year data on regional myocardial function in patients with severe fibrosis. For a better understanding of outcomes and their determinants, we compared baseline characteristics of patients who deceased in the course of the study versus the patients surviving up to the 10-year follow-up using t test or Fisher exact test, as appropriate. For the comparison of the groups according to baseline fibrosis presence (±), we chose parameters that showed significant differences in earlier measurements or were important to interpret the aforementioned parameters. As above, t test or Fisher exact tests were used, as appropriate. Survival has been compared between the groups using Kaplan-Meier plots and log-rank test. Parameters differing between survivors and nonsurvivors in Table 3 (P<0.05) were entered into univariate Cox proportional hazards regression analysis, and hazard ratios with the Wald coefficient are reported (Table 4) . These parameters were separately adjusted for age and sex (Table 4 , middle column), as well as the EuroSCORE (Table 4 , column on the right).
RESULTS
Baseline Clinical, Invasive, and Noninvasive Data Table 1 depicts the baseline characteristics of the study population as already published in 2009. 14 Significant differences could be noted between the 3 groups about NYHA functional class and the prevalence of atrial fibrillation, which was highest in the group with severe fibrosis (P=0.003). The invasively measured left ventricular pressures were lowest in the group with severe fibrosis, as was the stroke volume (P<0.001 and P=0.002, respectively), indicating reduced contractile capacity. Similarly, parameters of regional (septal longitudinal strain and septal longitudinal strain rate) and longitudinal (mitral ring displacement) left ventricular function were reduced in the group with severe fibrosis. Global function, that is, EF, showed no difference between the groups. As already published in our short-term study, 88% of the patients (n=14) with severe histological fibrosis had >1 late enhancement-positive segment. Patients from the group without histological replacement fibrosis, 89% (n=16) had no late enhancement in CMR, showing a good concordance of CMR late enhancement and histological amount of MRF. The distribution of focal fibrosis assessed by CMR is displayed in Figure 1 . Figure 2 shows an example of serial CMR scan of a patient without fibrosis and a patient with severe fibrosis. No patient in the total sample exhibited regression of MRF over the time period of 10 Table 2 shows changes in regional myocardial function in the 3 groups over the course of 10 years. The group without fibrosis showed a significant decline in regional myocardial function both in strain rate and in longitudinal strain (Figure 3 ). In the group with mild fibrosis, this effect could not be noted. Especially, a reduced NYHA functional class, higher prevalence of atrial fibrillation, and a worse EuroSCORE come to attention comparing baseline characteristics of the study population according to survival status at 10-year follow-up (Table 3 ). Figure 4 shows NYHA functional classes at follow-up intervals 14 . In the group without MRF, an improvement of NYHA functional class after AVR could be noted (Figure 4 ).
Clinical and Echocardiographic Data 10 Years After AVR
CMR Studies
CMR was used to rate the degree and monitor the progress of MRF at baseline and 9 months, as well as 10 years after AVR. The spatial pattern of MRF at baseline is demonstrated in Figure 1 . The average CMR amount overall 16 LV segments was significantly higher in group with mild and severe fibrosis compared with no fibrosis group (no fibrosis, 6.5±2.5%; mild fibrosis, 8.5±2.9%; and severe fibrosis, 9.7±2.2% (P=0.021). A detailed assessment of the distribution of focal fibrosis has also been published in the short-term outcome report of this study 14 Briefly, late enhancement-positive segments were found primarily at the subendocardial layer in the basal segments of the LV with a tendency toward the inferior and inferobasal segments ( Figure 1 ). 14 Unfortunately, 10-year CMR follow-up was only available in n=7 patients, 6 of whom were in no fibrosis group. Regarding the absolute amount of MRF, no significant changes could be noted during the 10-year follow-up (baseline amount of fibrosis out of 16 segments: 6.6±2.6% and 10-year follow-up out of 16 segments: 3.8±2.7%; P=0.125).
Survival Analysis for 10-Year Follow-Up
Patients with severe histological and CMR replacement fibrosis had a significantly worse outcome compared with patients without fibrosis, both for overall death (log-rank P=0.001) and cardiovascular death (log-rank P=0.010; Figure 5A and 5B). Similarly, presence of histological replacement fibrosis impacted on both death (log-rank P=0.03) and cardiovascular death (log-rank P=0.06; Figure 5B and 5C). Patients who deceased during follow-up had higher myocyte diameters and larger amounts of histologically confirmed replacement fibrosis than patients who survived (both P=0.008). A low flow-low gradient pattern was associated with poorer prognosis. Therefore survival probability was significantly better in patients with a mean transvalvular pressure gradient of >40 mm Hg ( Figure 5D and 5E) at 10-year follow-up. Table 5 shows several key clinical, as well as echocardiographic parameters at the 10-year followup grouped according to their baseline fibrosis status AV indicates aortic valve; CMR, cardiac magnetic resonance; E/E´, ratio of early diastolic mitral flow to early; HR, hazards ratio; and NYHA, New York Heart Association.
*Numbers for NYHA II were to small for statistical analysis.
(±): Patients without fibrosis at baseline were younger (P=0.037) and in better NYHA functional classes (P=0.019). The type of prosthesis was similar between groups, and no indication of prosthesis stenosis was found (Table 5 ). In Cox regression analysis, EuroSCORE, mitral annular plane systolic excursion (MAPSE), bioptic fibrosis score, and CMR fibrosis group remained independent predictors of poor outcome after adjusted for age and sex (Table 4) . Replacement fibrosis, assessed histologically or by CMR, was found to be independent predictor of the outcome (Table 4) . Although the CMRbased grading had a trend toward a higher area under the curve than the bioptic fibrosis score, no statistical difference could be noted in the z test (C statistic: bioptic fibrosis score, area under the curve 0.739; CI, 0.606-0.872; P=0.003; CMR based grouping: area under the curve 0.806; 95% CI, 0.692-0.920; P<0.001). When adjusted for EuroSCORE, MAPSE and severe CMR fibrosis group were found to be independent predictors of outcome.
DISCUSSION
This prospective clinical study provides evidence that in symptomatic severe AS, the presence of MRF is associated with increased all-cause and cardiovascular mortality risk, even 10 years after AVR. Replacement fibrosis is a common finding in AS patients, causing significant deterioration of regional myocardial contractility leading to a profound impact on long-term outcome. After 10 years of follow-up, no regression of replacement fibrosis could be noted. In this study, a good correlation between MRF and cardiac function was found measuring the displacement of the mitral ring or by using echocardiographic deformation imaging, such as strain or strain rate. As a consequence, any delay of AVR might increase the risk of the occurrence of fibrosis and thus contribute to poor long-term outcome. In addition, several parameters may serve as clinically useful predictors of bad prognosis, in particular a low gradient AS in the preoperative assessment.
Myocardial Fibrosis in Aortic Stenosis
Hypertrophy in AS arises as a consequence of various triggers: decreased myocardial perfusion and continuously increasing wall stress on the subendocardium, as well as neurohumoral activation of the renin-angiotensin system and matrix metalloproteinases. Starting at subendocardial layers, this first leads to interstitial and later, because of apoptosis triggered by these ischemic, mechanical, and neurohumoral factors, to replacement fibrosis. 16, 22 Progress in all these cascades can be indirectly measured apparent from the current study findings: invasively by cardiac biopsies, but also noninvasively by CMR including late enhancement, as well by echocardiography, measuring regional myocardial function for the assessment of the functional consequences. As suggested in several studies before, detection of replacement fibrosis by CMR is feasible and in good correlation with the histological results of myocardial biopsy. 18, 23 The present study supports these previous findings. To our knowledge, this study shows for the first time all these components together and prospectively over a period of 10 years. All these results are in line with prior selective studies investigating ≥1 of these components mentioned before. 12, 16, 18, 23 Besides invasive biopsies, the current reference stan- dard for the assessment of myocardial fibrosis, we used CMR to rate the degree and monitor the progress of fibrosis in our patients at baseline and 9 months and 10 years after AVR. Interestingly, there was no statistical increase of late enhancement after AVR. Replacement fibrosis stayed stable, and 1 might have expected at least slight progression in few patients most likely because of natural aging processes or probably influenced by comorbidities, such as uncontrolled hypertension or other cardiac comorbidities. Interestingly, in this 1 case that showed a progression of myocardial fibrosis. The basal segment of the left ventricle, usually being the typical distribution because of highest wall stress of pressure overload AS or prosthesis restenosis-associated replacement fibrosis, was not affected, thus indicating a different pathomechanism. 24 Of note, numbers of 10-year follow-up CMR were small and only available from patients with no baseline fibrosis. Therefore, this study cannot give a comprehensive answer to this issue.
Long-Term Outcome in AS
Ten years after AVR, a profound impact on all-cause and cardiac mortality could be seen because of the baseline presence of myocardial fibrosis, resulting in the lowest survival probability for patients with severe fibrosis of all groups. In direct comparison, patients with severe fibrosis at baseline had a significantly lower survival probability than patients without replacement fibrosis or only mild CMR fibrosis. Hence, the presence of fibrosis was associated with a poor prognosis. Nevertheless, we showed a good correlation of CMR and histological fibrosis, but there is no difference between absent and only MRF by CMR groups. Only at least >6.5% of all 16 segments of the LV is associated with poor outcome. Long-term data showed that for good clinical outcome and survival, it is essential to have preserved myocardial function, which reflects best by longitudinal functional parameters like strain rate and MAPSE. This is in good accordance to several studies in asymptomatic, as well as symptomatic AS patients. [25] [26] [27] So far, the guidelines for the assessment and therapeutic management in AS patients warrant an EF <50% for the AVR indication in asymptomatic patients. One main issue is that although EF remains preserved, replacement fibrosis may already have developed, drastically reducing the chances for a good long-term outcome after AVR. Even though we did not examine asymptomatic patients in this study, 70% of patients had an EF >50% with CMR and biopsy confirmed replacement fibrosis. These findings confirm the need for outcome studies investigating the impact of replacement fibrosis in asymptomatic patients with AS. The present study demonstrates that, along with current risk scores such as the EuroSCORE, functional parameters reflecting LV longitudinal function such as MAPSE are independent predictors of poor outcome. The role of MAPSE as independent predictor of survival in the present study is in line with previous data on the correlation of replacement fibrosis and longitudinal LV function. 7 A recently published study on asymptomatic AS demonstrated that a clinical risk score consisting of variables associated with mid-wall myocardial fibrosis enables strong prognostic information in asymptomatic patients with AS and holds major potential in identifying those who may benefit from early AVR. 28 Fur- thermore, the present study supports a preoperative diagnostic approach that emphasizes a detailed assessment of functional abnormalities of the LV myocardium beside the EF as more sensitive parameters of LV functional impairment to avoid any delay in AVR and the consequence of a poor long-term outcome (Figure 3) . Especially against the background of a perioperative mortality of 1% to 3% nowadays for a surgical AVR and the knowledge from our study that there was no cardiac death after 10 years for patients showing no fibrosis at baseline. Similar results could be seen in asymptomatic patients either treated surgically or with a watchful waiting strategy with a favorable outcomes for patients with an early treatment strategy. 29 Thus, properly evalu- ating the surgical risk in case of atrial fibrillation or low gradient AS, which is associated with a 4-fold increase of myocardial fibrosis and poor clinical outcomes and higher perioperative and long-term mortality after AVR, is essential before making final treatment decision. This should be explained carefully and discussed in detail in the heart team and to patients before they get sent to AVR or for a joint decision of the procedure itself either surgical or interventional.
Limitations
After AVR, clinical outcome was assessed only by NYHA functional class. A 6-minute walking test might have allowed a more precise quantification of exercise capacity after AVR. A specific testing for amyloidosistrans-thyretin cardiac amyloidosis was not performed, despite given recent reports of relatively high incidence of amyloidosis-trans-thyretin amyloidosis in SAVR in elderly patients, so that observed outcomes could have been affected by this disease. The limited tissue sampling and pathological identification of fibrosis may not be representative of the LV as a whole. Speckle tracking analysis, which is the current reference standard in the assessment of strain and strain rate, could not be used in this study because in 2006 it was not yet available. Also, CMR imaging underwent significant improvements since the conception of the present study, for example, novel now widely available techniques, such as T1 mapping might yield additional information about quantification of diffuse fibrosis. The present study was not powered to allow for a multivariate Cox regression analysis to directly compare the different risk factors among each other. However, it has never been the goal of this study to find the most powerful predictor of outcome in patients undergoing AVR. The present study is intended to add to the understanding of AS and the pathophysiologic impact of coexistent replacement fibrosis.
Conclusions
This 10-year follow-up study underlines the profound impact of replacement fibrosis in patients undergoing AVR for severe AS. Integrating CMR and echocardiographic functional imaging beyond EF quantification could help in clinical decision making to identify patients with good prognosis, in whom myocardial longitudinal function is still preserved and replacement fibrosis not yet present.
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